Niels Reinmuth - Researcher Profile | RDL Research Database

Publications

3 shown

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares , Mikhail Dvorkin , Yuanbin Chen +97 more

2019 The Lancet 2014 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst , Giuseppe Giaccone , Filippo de Marinis +19 more

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of his...

2020 New England Journal of Medicine 1580 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 4
Citations: 7,205
Institution: Asklepios Fachkliniken München-Gauting

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-7369-4512

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.